EGFR and non-small cell lung carcinoma: TKIs are divided into first-generation reversible inhibitors targeting EGFR and HER2 (gefitinib, erlotinib, lapatinib), second-generation irreversible inhibitors (afatinib, dacomitinib, neratinib), and third-generation inhibitors, which are improved drugs to overcome resistance to first-generation TKIs in the treatment of NSCLC (AZD9291, CLO-1686) [22].